Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Companyā€™s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.
ļ»æ

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > šŸ¦ COVID-19 Mutations is Accelerating ~ A SolutionšŸŠļ»»
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3)
•••
Comment by ApricotKernelon Mar 14, 2021 4:37am
175 Views
Post# 32794347

RE:šŸ¦ COVID-19 Mutations is Accelerating ~ A SolutionšŸŠļ»»

RE:šŸ¦ COVID-19 Mutations is Accelerating ~ A SolutionšŸŠļ»»
GAJJARDR wrote: Claritas believes that R-107 has potential to become an effective front-line therapy for patients who contract COVID-19 infection. The Company believes that R-107 may also have potential as a prophylactic to prevent COVID-19 infection, and the Company intends to also develop R-107 as a nasal spray for this purpose.

Since the emergence of COVID-19 in December 2019, the original strain from Wuhan, China has mutated into more than 80 new strains. This is a remarkably rapid rate of mutation. The introduction of vaccines into the general population beginning in 2021 is expected to accelerate the rate of mutation of COVID-19 because the strains susceptible to vaccination will be replaced by new and emergent strains that have evaded the immune response.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities